Trial Profile
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2023
Price :
$35
*
At a glance
- Drugs Letetresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Myxoid liposarcoma
- Focus Therapeutic Use
- Sponsors Adaptimmune; GlaxoSmithKline; GSK
- 07 Jun 2022 Primary efficacy and safety results were presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 04 Apr 2022 Status changed from active, no longer recruiting to completed.
- 15 Oct 2021 Planned End Date changed from 15 Oct 2021 to 1 Aug 2022.